Catalyst Wire Dossier Catalyst Wire Dossier

Liposome-encapsulated irinotecan (PEP02)

liposomal irinotecan
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Liposome-encapsulated irinotecan (PEP02), covering 2015-06-04 to 2015-06-04. Get the full timeline:

Most recent: Clinical Trial Update: Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer [Phase 2]

See pricing